Exscientia's CEO shares a pipeline overview and learnings from being one of the first AI companies out front and to go public

blonca9
May 2, 2024
1 min read

Dave Hallett gives an overview of Exscientia and describes how important testing compounds in the company's labs has been to its iterative process that is founded in AI.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Exscientia's CEO shares a pipeline overview and learnings from being one of the first AI companies out front and to go public

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight